glp-1 use in type 1 diabetes SGLT2i and RA therapy and reno-vascular outcomes: a real-world study | Diabetologia GLP-1-based therapies for diabetes, obesity

Plaintiffs had also raised concerns that the early discovery process could put the NAION litigation out of sync with Marstons separate GLP-1 stomach paralysis MDL, which involves thousands of cases and is proceeding toward its own independent bellwether process

Haase H, Ober-Blobaum JL, Engelhardt G, Hebel S, Heit A, Heine H, et al

Also, we solicited public comment on the proposal to modify the regulation at 414.1380(b)(4)(ii)(C) to clarify the scoring of optional bonus measures under the Public Health and Clinical Data Exchange objective beginning with the CY 2026 performance period/2028 MIPS payment year

Access can change as evidence and regulatory decisions change

FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity medicalxpress.com To view or add a comment, sign in FDA Approval Update: Foundayo (orforglipron) On April 1, 2026, the U.S